NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”).  On October 14, 2014, at the annual meeting of the Shareholders’ of the Company, a proposal was passed to change the name of the Company from Health Enhancement Products, Inc. to Zivo Bioscience, Inc.  On October 16, 2014, the Amended Articles of Incorporation and effecting the name change were filed with the State of Nevada.  On October 30, 2014,  Financial Industry Regulatory Authority (FINRA) approved the name Zivo Bioscience, Inc. for trading purposes and the symbol change to ZIVO effective November 10, 2014.  All significant inter-company accounts and transactions have been eliminated in consolidation.  In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein.  These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s  December 31, 2013 consolidated audited financial statements and supplementary data included in the Annual Report on Form 10-K filed with the SEC on March 31, 2014.

The results of operations for the nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2014, or any other period.

The Company had a loss from operations of $2,675,910 and $2,305,887 for the nine months ended September 30, 2014 and 2013, respectively.  In addition, the Company had a working capital deficiency of $9,028,139 and a stockholders’ deficit of $8,043,251 at September 30, 2014.  These factors continue to raise substantial doubt about the Company's ability to continue as a going concern.  During the first nine months of 2014, the Company raised $735,500 in net proceeds from the issuance of common stock and the exercise of warrants to purchase common stock, $1,285,000 from the issuance of convertible debentures and $28,010 from a loan payable to a related party.  There can be no assurance that the Company will be able to raise additional capital.

The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.